Elucidating the immune mechanism of CD8+ TILs/PD‐L1 TC and CD8+ TILs/CD4+CD25+FOXP3+ Treg ratios may provide strategies for developing immunotherapy for ESCC. This evidence concerns the gene FOXP3 and esophageal squamous cell carcinoma.